CORRESP Filing
GT Biopharma, Inc.
Date: Jan. 28, 2026 · CIK: 0000109657 · Accession: 0001493152-26-003958
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292856
Letter
GT Biopharma, Inc.
Montgomery Street, 10th Floor
San Francisco, California 94111
January 28, 2026
VIA EDGAR
Division of Corporation Finance
United States Securities and Exchange Commission
F Street, N.E.
Washington, D.C. 20549
Attn: Jimmy McNamara
Re: GT Biopharma, Inc.
Acceleration Request for Registration Statement on Form S-1
File No. 333-292856
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), GT Biopharma, Inc. (the " Company ") hereby requests that the effective date of the above-referenced registration statement (the " Registration Statement ") be accelerated to January 30, 2026, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
We request that we be notified of such effectiveness by a telephone call to Alan A. Lanis, Jr. of Baker & Hostetler LLP, counsel to the Company, at (310) 442-8850 and that such effectiveness also be confirmed in writing.
Very
truly yours,
GT
Biopharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm GT Biopharma, Inc. 505 Montgomery Street, 10th Floor San Francisco, California 94111 January 28, 2026 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: GT Biopharma, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-292856 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the " Act "), GT Biopharma, Inc. (the " Company ") hereby requests that the effective date of the above-referenced registration statement (the " Registration Statement ") be accelerated to January 30, 2026, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Baker & Hostetler LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act. We request that we be notified of such effectiveness by a telephone call to Alan A. Lanis, Jr. of Baker & Hostetler LLP, counsel to the Company, at (310) 442-8850 and that such effectiveness also be confirmed in writing. Very truly yours, GT Biopharma, Inc. By: /s/ Alan Urban Alan Urban Chief Financial Officer